Treatment-naïve group (n = 8) | Prior ERT group (n = 93) | Prior ERT and SRT group (n = 5)a | Total patients (N = 106) | |
---|---|---|---|---|
Total TEAEs, n | 15 | 78 | 2 | 95 |
Total treatment-related TEAEs, n | 1 | 20 | 0 | 21 |
Patients with TEAEs, n (%) | 4 (50.0) | 34 (36.6) | 1 (20.0) | 39 (36.8) |
Patients with treatment-related TEAEs, n (%) | 1 (12.5) | 11 (11.8) | 0 (0.0) | 12 (11.3) |
Patients with SAEs, n (%) | 1 (12.5) | 10 (10.8) | 1 (20.0) | 12 (11.3) |
Patients with treatment-related SAEs, n (%) | 0 (0.0) | 2 (2.2) | 0 (0.0) | 2 (1.9) |
Patients with severe TEAEs | 1 (12.5) | 6 (6.5) | 1 (20.0) | 8 (7.5) |
Patients with treatment-related severe TEAEs | 0 (0.0) | 2 (2.2) | 0 (0.0) | 2 (1.9) |
Patients with discontinuations due to TEAEsb, n (%) | 0 (0.0) | 4 (4.3) | 0 (0.0) | 4 (3.8) |
Patients with all-cause mortality, n (%) | 0 (0.0) | 4 (4.3) | 0 (0.0) | 4 (3.8) |